These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35313504)

  • 21. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
    Julander JG; Testori M; Cheminay C; Volkmann A
    Front Immunol; 2018; 9():1756. PubMed ID: 30116244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice.
    Ma J; Boudewijns R; Sanchez-Felipe L; Mishra N; Vercruysse T; Buh Kum D; Thibaut HJ; Neyts J; Dallmeier K
    Emerg Microbes Infect; 2021 Dec; 10(1):2279-2290. PubMed ID: 34792431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A clinician's perspective on yellow fever vaccine-associated neurotropic disease.
    Lecomte E; Laureys G; Verbeke F; Domingo Carrasco C; Van Esbroeck M; Huits R
    J Travel Med; 2020 Nov; 27(7):. PubMed ID: 32965473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes.
    Barba-Spaeth G; Longman RS; Albert ML; Rice CM
    J Exp Med; 2005 Nov; 202(9):1179-84. PubMed ID: 16260489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports.
    Croce E; Hatz C; Jonker EF; Visser LG; Jaeger VK; Bühler S
    Vaccine; 2017 Mar; 35(9):1216-1226. PubMed ID: 28162821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case suspected for yellow fever vaccine-associated viscerotropic disease in the Netherlands.
    van de Pol EM; Gisolf EH; Richter C
    J Travel Med; 2014; 21(6):421-4. PubMed ID: 24920138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small-molecule inhibitors of TBK1 serve as an adjuvant for a plasmid-launched live-attenuated yellow fever vaccine.
    Sharma S; Schmid MA; Sanchez Felipe L; Grenelle J; Kaptein SJF; Coelmont L; Neyts J; Dallmeier K
    Hum Vaccin Immunother; 2020 Sep; 16(9):2196-2203. PubMed ID: 32574095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Yellow fever vaccine-associated neurotropic disease (YEL-AND) - A case report.
    Florczak-Wyspiańska J; Nawotczyńska E; Kozubski W
    Neurol Neurochir Pol; 2017; 51(1):101-105. PubMed ID: 27707454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Japanese encephalitis virus/yellow fever virus chimera is safe and confers full protection against yellow fever virus in intracerebrally challenged mice.
    Yang H; Yang H; Li Z; Liu L; Wang W; He T; Fan F; Sun Y; Liu J; Li Y; Zeng X
    Vaccine; 2018 Apr; 36(18):2450-2455. PubMed ID: 29580643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
    Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
    Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD).
    Seligman SJ
    Vaccine; 2014 Oct; 32(44):5769-75. PubMed ID: 25192973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse event reports following yellow fever vaccination, 2007-13.
    Lindsey NP; Rabe IB; Miller ER; Fischer M; Staples JE
    J Travel Med; 2016 May; 23(5):. PubMed ID: 27378369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
    Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
    Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Present and Future of Yellow Fever Vaccines.
    Hansen CA; Barrett ADT
    Pharmaceuticals (Basel); 2021 Sep; 14(9):. PubMed ID: 34577591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against Viral Challenge in Animal Models.
    Tottey S; Shoji Y; Jones RM; Chichester JA; Green BJ; Musiychuk K; Si H; Manceva SD; Rhee A; Shamloul M; Norikane J; Guimarães RC; Caride E; Silva ANMR; Simões M; Neves PCC; Marchevsky R; Freire MS; Streatfield SJ; Yusibov V
    Am J Trop Med Hyg; 2018 Feb; 98(2):420-431. PubMed ID: 29231157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi.
    Nogueira RT; Nogueira AR; Pereira MC; Rodrigues MM; Neves PC; Galler R; Bonaldo MC
    PLoS One; 2013; 8(3):e59347. PubMed ID: 23527169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaques.
    Martins MA; Bonaldo MC; Rudersdorf RA; Piaskowski SM; Rakasz EG; Weisgrau KL; Furlott JR; Eernisse CM; Veloso de Santana MG; Hidalgo B; Friedrich TC; Chiuchiolo MJ; Parks CL; Wilson NA; Allison DB; Galler R; Watkins DI
    PLoS One; 2013; 8(1):e54434. PubMed ID: 23336000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A mouse model for studying viscerotropic disease caused by yellow fever virus infection.
    Meier KC; Gardner CL; Khoretonenko MV; Klimstra WB; Ryman KD
    PLoS Pathog; 2009 Oct; 5(10):e1000614. PubMed ID: 19816561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Limited potential for transmission of live dengue virus vaccine candidates by Aedes aegypti and Aedes albopictus.
    Sardelis MR; Edelman R; Klein TA; Innis BL; Putnak JR; Jones JW; Turell MJ
    Am J Trop Med Hyg; 2000 Jun; 62(6):698-701. PubMed ID: 11304057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes.
    Johnson BW; Chambers TV; Crabtree MB; Bhatt TR; Guirakhoo F; Monath TP; Miller BR
    Am J Trop Med Hyg; 2002 Sep; 67(3):260-5. PubMed ID: 12408664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.